SecurityUAN / CVR Partners, LP (126633106)
President and CEOPYTOSH MARK A
IndustryAgricultural Chemicals
Institutional Owners59
Institutional Shares37,402,557 - 33.02%
Common Shares Outstanding113,282,973 shares (as of 2018-06-30)
Institutional Value$ 124,038,000 USD

Institutional Stock Ownership and Shareholders

CVR Partners, LP (NYSE:UAN) has 59 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 37,402,557 shares. Largest shareholders include Goldman Sachs Group Inc, Morgan Stanley, Raging Capital Management, LLC, Blackstone Group L.P., HITE Hedge Asset Management LLC, Barclays Plc, JP Morgan Chase & Co, UBS Group AG, Glendon Capital Management LP, and Cna Financial Corp.
CVR Partners, LP (NYSE:UAN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 2,866 11,674 307.33 9 39 333.33
2018-08-10 13F-HR Hartford Financial Management Inc. 4,000 13
2018-07-20 13F-HR America First Investment Advisors, LLC 255 0 -100.00 1 0 -100.00
2018-08-02 13F-HR BABSON CAPITAL MANAGEMENT LLC 126,319 126,319 0.00 411 417 1.46
2018-07-18 13F-HR Sawyer & Company, Inc 4,315 4,315 0.00 14 14 0.00
2018-08-14 13F-HR CREDIT SUISSE AG/ 203,900 0 -100.00 663 0 -100.00
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 174,118 22,427 -87.12 566 74 -86.93
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 86,600 37,000 -57.27 281 122 -56.58
2018-08-14 13F-HR Blackstone Group L.P. 5,307,821 5,307,821 0.00 17,250 17,516 1.54
2018-09-18 13F-HR/A NORTHERN TRUST CORP 15,392 51
2018-08-10 13F-HR Greenwich Investment Management, Inc. 23,099 20,781 -10.04 75 69 -8.00
2018-08-13 13F-HR Advisor Group, Inc. 3,555 3,555 0.00 11 11 0.00
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 170,100 173,337 1.90 553 572 3.44
2018-08-06 13F-HR SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) 473 0 -100.00 2 0 -100.00
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Call 30,700 1,200 -96.09 100 4 -96.00
2018-08-14 13F-HR Prime Capital Investment Advisors, Llc 15,000 15,000 0.00 49 50 2.04
2018-07-30 13F-HR SIMPLEX TRADING, LLC Put 28 8 -71.43 1 2 100.00
2018-07-30 13F-HR SIMPLEX TRADING, LLC Call 3 10 233.33 0 3
2018-08-16 13F-HR/A COWEN GROUP, INC. 171,079 565
2017-01-13 13F-HR MetLife Securities, Inc 4,665 4,775 2.36 25 29 16.00
2018-08-03 13F-HR PEKIN SINGER STRAUSS ASSET MANAGEMENT /IL 10,000 0 -100.00 32 0 -100.00
2018-08-14 13F-HR SevenBridge Financial Group, LLC 944 944 0.00 3 3 0.00
2018-08-01 13F-HR FIRST MANHATTAN CO 45,000 110,000 144.44 209 363 73.68
2018-08-13 13F-HR RAYMOND JAMES & ASSOCIATES 29,479 29,479 0.00 96 97 1.04
2018-08-14 13F-HR LPL Financial LLC 144,216 136,789 -5.15 469 451 -3.84
2018-08-16 13F-HR Global X Management CO LLC 27,202 33,401 22.79 88 110 25.00
2018-08-14 13F-HR Intrinsic Edge Capital Management LLC 150,000 495
2018-08-14 13F-HR BARCLAYS PLC Call 5,600 3,600 -35.71 18 12 -33.33
2018-08-10 13F-HR Ahrens Investment Partners Llc 18,050 16,450 -8.86 58 54 -6.90
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Put 18,200 0 -100.00 59 0 -100.00
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 0 12,500 0 41
2018-08-14 13F-HR Nuveen Fund Advisors, LLC 35,499 30,035 -15.39 115 99 -13.91
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 8,125,946 7,140,605 -12.13 26,409 23,564 -10.77
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Put 4,500 0 -100.00 15 0 -100.00
2018-08-01 13F-HR Hudock Capital Group, LLC 0 500 0 1
2018-08-13 13F-HR Stockman Asset Management 11,180 11,180 0.00 36 37 2.78
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 17,965 0 -100.00 58 0 -100.00
2018-08-02 13F-HR IndexIQ Advisors LLC 15,419 17,856 15.81 50 59 18.00
2018-08-08 13F-HR US BANCORP \DE\ 1,540 1,540 0.00 5 5 0.00
2018-08-14 13F-HR NWQ INVESTMENT MANAGEMENT COMPANY, LLC 967,190 0 -100.00 3,143 0 -100.00
2018-08-14 13F-HR UBS Group AG 86,110 1,766,720 1,951.70 279 5,831 1,989.96
2018-08-14 13F-HR DEUTSCHE BANK AG\ 3,702 0 -100.00 11 0 -100.00
2018-08-13 13F-HR CNA FINANCIAL CORP 502,664 502,664 0.00 1,634 1,659 1.53
2018-08-10 13F-HR CITIGROUP INC 0 149,060 0 492
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 1,001 1,001 0.00 3 3 0.00
2018-08-14 13F-HR Glendon Capital Management LP 546,279 1,202,960 120.21 1,775 3,970 123.66
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 440,154 204,167 -53.61 1,431 674 -52.90
2018-07-30 13F-HR SIMPLEX TRADING, LLC 1,709 922 -46.05 5 3 -40.00
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 82,358 82,358 0.00 268 268 0.00
2018-08-08 13F-HR BRONFMAN E.L. ROTHSCHILD, L.P. 1,804 1,804 0.00 6 6 0.00
2018-08-03 13F-HR Seacrest Wealth Management, Llc 912 912 0.00 3 3 0.00
2018-08-14 13F-HR Jefferies Group LLC 175,000 0 -100.00 569 0 -100.00
2018-08-14 13F-HR JP Morgan Chase & Co 2,041,696 1,944,831 -4.74 6,636 6,418 -3.29
2018-08-03 13F-HR WEDBUSH SECURITIES INC 12,148 0 -100.00 39 0 -100.00
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 16,570 74,669 350.63 54 246 355.56
2018-07-30 13F-HR/A Virtu Financial LLC 23,876 38,595 61.65 78 128 64.10
2018-08-14 13F-HR MORGAN STANLEY 2,872,537 6,490,462 125.95 9,336 21,418 129.41
2018-08-14 13F-HR PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 0 65,604 0 216
2018-08-14 13F-HR Aspen Investment Management Inc 12,000 40
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Call 0 15,700 0 52
2018-08-14 13F-HR BARCLAYS PLC 2,229,730 2,217,723 -0.54 7,247 7,319 0.99
2017-01-27 13F-HR Strategic Income Management, LLC 213,218 213,218 0.00 1,130 1,281 13.36
2018-08-10 13F-HR MARCO INVESTMENT MANAGEMENT LLC 23,528 22,500 -4.37 76 74 -2.63
2018-08-14 13F-HR/A Quinn Opportunity Partners LLC 84,430 84,430 0.00 274 279 1.82
2018-08-13 13F-HR HITE Hedge Asset Management LLC 849,244 2,256,692 165.73 2,760 7,447 169.82
2018-08-07 13F-HR IFP Advisors, Inc 7,937 7,937 0.00 26 26 0.00
2017-01-23 SC 13D/A RENTECH, INC. 7,187,630
2018-08-14 13F-HR Raging Capital Management, LLC 9,572,033 6,185,798 -35.38 31,109 20,413 -34.38
2018-08-09 13F-HR GSA CAPITAL PARTNERS LLP 214,524 0 -100.00 697 0 -100.00
2018-08-10 13F-HR FORBES J M & CO LLP 14,900 14,900 0.00 48 49 2.08
2018-08-14 13F-HR Credit Capital Investments LLC 472,274 262,520 -44.41 1,535 890 -42.02
2018-08-02 13F-HR Sigma Planning Corp 11,187 37
2018-08-14 13F-HR BARCLAYS PLC Put 12,400 5,100 -58.87 40 17 -57.50
2018-08-03 13F-HR SEI INVESTMENTS CO 5,317 0 -100.00 17 0 -100.00
2018-08-09 13F-HR Bollard Group LLC 424 424 0.00 1 1 0.00
2018-08-14 13F-HR SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC 16,600 11,900 -28.31 54 39 -27.78
2018-07-26 13F-HR REGIONS FINANCIAL CORP 8,120 8,120 0.00 26 26 0.00
2018-08-10 13F-HR Cutler Group LP 5,512 2,500 -54.64 17 8 -52.94
2018-08-14 13F-HR ROYAL BANK OF CANADA 5,625 4,725 -16.00 18 16 -11.11

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Fertilizer Industry Looking Up: 3 Stocks to Buy Now

2018-09-13 zacks
The fertilizer industry is gradually gaining momentum, courtesy of an improving demand and pricing dynamics for major crop nutrients. Healthy global demand along with reduced supply, especially from China, is providing support to global prices of nitrogen, a major crop input. Moreover, prices of phosphate and potash have gained strength this year on the back of strong global demand. Fertilizer makers are poised to gain from favorable nutrient demand and pricing in the near future.

Tracking Carl Icahn's Portfolio - Q2 2018 Update

2018-09-03 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018. (57-3)

Icahn Enterprises LP (IEP) CEO Keith Cozza on Q2 2018 Results - Earnings Call Transcript

2018-08-02 seekingalpha
Good day, and welcome to Icahn Enterprises L.P. Q2 2018 Earnings Conference Call with Jesse Lynn, General Counsel; Keith Cozza, President and CEO; and SungHwan Cho, Chief Financial Officer. I would now turn the call over to Jesse Lynn who will read the opening statements. (10-0)

Strong Buy Rating On An Energy Stock With 7% Dividend And 20% Upside Potential

2018-07-27 seekingalpha
Review of CVR Energy, an energy stock predicted to outperform the market for the next 6-12 months. (0-1)

CVR Partners' (UAN) Q2 Earnings Beat Estimates, Sales Fall

2018-07-26 zacks
CVR Partners, LP (UAN - Free Report) logged a loss of $16 million or 15 cents per share in the second quarter of 2018, wider than a loss of $4 million or 3 cents per share it recorded a year ago. The reported loss per share was, however, narrower than the Zacks Consensus Estimate of a loss of 24 cents. CVR Partners raked in net sales of $93 million, down around 5% year over year. (1-0)

What's in the Cards for CVR Partners (UAN) in Q2 Earnings?

2018-07-23 zacks
CVR Partners, LP (UAN - Free Report) is set to release second-quarter 2018 results, after the bell on Jul 25. CVR Partners logged a loss of $19 million or 17 cents per share in the first quarter, wider than a loss of $10 million or 9 cents it posted a year ago. The loss per share was also wider than the Zacks Consensus Estimate of a loss of 13 cents, translating into a negative surprise of 30.8%. The results were affected by downtime at the company’s East Dubuque plant. (1-0)

Tracking Carl Icahn's Portfolio - Q1 2018 Update

2018-05-21 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's 13F portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017. (212-7)

MLPs: Buy After Distribution Cuts Or Run Away?

2018-05-17 seekingalpha
Many income investors sell on cuts to dividends and distributions. Other investors take a vulture-like approach and buy. Who is right? (27-0)

Icahn Enterprises' (IEP) CEO Keith Cozza on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Good morning and welcome to the Icahn Enterprises LP Q1 2018 Earnings Call with Jesse Lynn, General Counsel; Keith Cozza, President and CEO and SungHwan Cho, Chief Financial Officer. I would now like to hand over the call to Jesse Lynn who will read the opening statement. (14-1)

CVR Partners' (UAN) Q1 Earnings Lag Estimates, Sales Fall

2018-04-27 zacks
CVR Partners, LP (UAN - Free Report) posted a loss of $19 million or 17 cents per share in the first quarter of 2018, wider than a loss of $10 million or 9 cents per share it logged a year ago. The reported loss per share was also wider than the Zacks Consensus Estimate of a loss of 13 cents. CVR Partners raked in net sales of $80 million, down around 5.9% year over year. The company’s Coffeyville fertilizer plant performed well during the quarter, recording on-stream rates of 100% for gasification, 99. (16-0)

CUSIP: 126633106